Oncology and Hematology

97-112 of 219

• 

  MinuteCE®

  Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity

  Joshua Richter, MD; Sagar Lonial, MD, FACP

  1.00 credit 10 episodes

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Noopur Raje, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  MinuteCE®

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  Noopur Raje, MD

  1.00 program credit

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  MinuteCE®

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  Joshua Richter, MD; Sagar Lonial, MD, FACP

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  MinuteCE®

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  Joshua Richter, MD; Noopur Raje, MD

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  MinuteCE®

   Real-World Ready: Practical Tips for Community Oncologists

  Joshua Richter, MD; Sagar Lonial, MD, FACP

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  CME/CE

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  Heather Wakelee, MD, FASCO

  0.25 credits

  • 

    

    Heather Wakelee, MD, FASCO

  0.25 credits

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  Hussein Tawbi, MD, PhD; Sapna Patel, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  Sapna Patel, MD; John M. Kirkwood, MD

  1.00 program credit

  • 

    

    Sapna Patel, MD

  • 

    

    John M. Kirkwood, MD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  John M. Kirkwood, MD; Paolo A. Ascierto, MD

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  Paolo A. Ascierto, MD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  Hussein Tawbi, MD, PhD; Sapna Patel, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  John M. Kirkwood, MD; Sapna Patel, MD

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• Previous
• 1
• 2
• …
• 5
• 6
• 7
• 8
• 9
• …
• 13
• 14
• Next